new glp 1 drugs in development Emerging Trends the of GLP-1 Receptor Agonists Evolution of GLP‐1 Receptor Agonists

Kerem, L

Afshin AH, Forouzanfar M, Reitsma MB et al

Chemical synthesis and subsequent in vivo evaluation of a GIP/GLP-1MK-801 co-agonist conjugate revealed enhanced weight loss in DIO mice compared with mice treated with the GIP/GLP-1 co-agonist alone (Extended Data Fig

[1]International Diabetes Federation, IDF Diabetes Atlas 2024, International Diabetes Federation, diabetesatlas.org Mexico's 2023 documented 38.9 percent of obesity prevalence among adults, while 37.3 percent of the population is classified as overweight or obese, creating a high patient pool of individuals

On GLP-1 meds, managing appetite and ensuring adequate protein intake are key

This resistance has been linked to chronic health conditions such as heart disease, fatty liver disease, and cognitive decline